Medtronic Pays $43M To Settle Shareholder Suit Over Infuse Bone Graft Studies

Mealey's (July 25, 2018, 12:44 PM EDT) -- MINNEAPOLIS — Medtronic Inc. and four individual defendants on July 1 agreed to a $43 million class settlement involving alleged securities violations related to Medtronic’s reporting of risks with the Infuse bone graft device in clinical trials (In Re:  Medtronic, Inc., Securities Litigation, No. 13-1686, D. Minn.)....